Rate of relapses ( @/@ -LSB- @ % -RSB- placebo ; @/@ -LSB- @ % -RSB- pali ER ) and secondary endpoints ( change from baseline in Positive And Negative Syndrome Scale -LSB- PANSS -RSB- and Clinical Global Impression - Severity Scores ) were significantly lower ( p < @ ) in pali ER group vs placebo , in favor of pali ER .